The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...
Nichola Hawes is on trial for alleged fraud and selling or supplying medicines without proper prescriptions.
The Trump administration has promised that addressing childhood obesity will be a key part of its “Make America Healthy Again ...
23h
Hosted on MSNHims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugsThe telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.
This week, the FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat: True or False: Two new trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results